Intermediate for Ibrutinib. Ibrutinib (trade name: Imbruvica) is a small Bruton's tyrosine kinase (BTK) inhibitor. Ibrutinib is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia, a form of non-Hodgkin's lymphoma. Ibrutinib has been approved by the U.S Food and Drug Administration on November 19, 2013.
Product Name: (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyriMidin-4-aMine
CAS Number: 1022150-12-4
Molecular Weight:  386.4554
Molecular Formula:  C22H22N6O
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.